Veterinary Medicines

Clindabactin 440 mg Chewable Tablets for Dogs

Authorised
  • Clindamycin hydrochloride
Download as PDF

Product identification

Medicine name:
Clindabactin 440 mg Chewable Tablets for Dogs
Clindabactin 440 mg tuggutöflur handa hundum
Active substance:
  • Clindamycin hydrochloride
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Clindamycin hydrochloride
    440.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Chewable tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01FF01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Iceland
Package description:
  • Aluminium - Polyamide/Aluminium/PVC blister. Cardboard box containing 10 separate cardboard boxes, each containing 1 blister of 10 tablets.
  • Aluminium - Polyamide/Aluminium/PVC blister.Cardboard box of 8 blisters of 10 tablets.
  • Aluminium - Polyamide/Aluminium/PVC blister.Cardboard box of 6 blisters of 10 tablets.
  • Aluminium - Polyamide/Aluminium/PVC blister.Cardboard box of 4 blisters of 10 tablets.
  • Aluminium - Polyamide/Aluminium/PVC blister.Cardboard box of 3 blisters of 10 tablets.
  • Aluminium - Polyamide/Aluminium/PVC blister.Cardboard box of 25 blisters of 10 tablets.
  • Aluminium - Polyamide/Aluminium/PVC blister.Cardboard box of 1 blister of 10 tablets.
  • Aluminium - Polyamide/Aluminium/PVC blister.Cardboard box of 9 blisters of 10 tablets.
  • Aluminium - Polyamide/Aluminium/PVC blister.Cardboard box of 7 blisters of 10 tablets.
  • Aluminium - Polyamide/Aluminium/PVC blister.Cardboard box of 5 blisters of 10 tablets.
  • Aluminium - Polyamide/Aluminium/PVC blister.Cardboard box of 2 blisters of 10 tablets.
  • Aluminium - Polyamide/Aluminium/PVC blister.Cardboard box of 10 blisters of 10 tablets.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Dechra Regulatory B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lelypharma B.V.
Responsible authority:
  • Icelandic Medicines Agency
Authorisation number:
  • IS/2/19/005/03
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0317/003
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."